ISO 10993 is often treated as a late-stage biocompatibility testing list. That is where teams get into trouble. The standard is most useful when it is applied early, while material choices, manufacturing processes, device design, and regulatory strategy can still be shaped with biological safety in mind.
ISO 10993 starts with risk, not tests
ISO 10993-1 frames biological evaluation as evaluation and testing within a risk management process. The point is not to run every possible test. The point is to understand the device, identify biological risks, review existing evidence, and determine where gaps remain.
For early-stage teams, this distinction matters. A thoughtful biological evaluation may draw from material history, supplier information, literature, prior device experience, chemical characterization, toxicological assessment, predicate information, and targeted testing. The best strategy is not always the longest test battery. It is the one that answers the right risks clearly.
Start with body contact and duration
Biological evaluation depends heavily on how the device contacts the body. Does it contact intact skin, breached or compromised surfaces, mucosa, tissue, bone, blood, or circulating blood? Is contact limited, prolonged, or long-term?
These details influence which biological endpoints may need to be considered. A short-term, intact-skin-contacting device and a long-term implant should not be evaluated with the same assumptions.
Material choices are only part of the story
Biocompatibility is not only about the base material. Processing aids, adhesives, coatings, colorants, sterilization, packaging, cleaning residues, degradation products, and manufacturing changes can all affect biological safety. A material that looks acceptable on paper may still need evaluation in the context of the finished device.
That is why ISO 10993 planning should be connected to design controls, supplier decisions, change control, sterilization planning, and risk management.
Testing should follow the biological evaluation plan
A biological evaluation plan should explain the device, materials, intended use, patient contact, identified biological risks, available evidence, and remaining gaps. Testing should be selected because it addresses those gaps, not because it appears on a generic list.
Common endpoints may include cytotoxicity, sensitization, irritation or intracutaneous reactivity, systemic toxicity, material-mediated pyrogenicity, genotoxicity, implantation, hemocompatibility, or other endpoints depending on contact and risk.
Why this matters before the design is locked
When ISO 10993 planning happens late, teams may discover that the tested device was not representative, that material documentation is incomplete, or that the selected test plan does not match the regulatory question. Early planning reduces the chance of repeated testing, unclear reports, or submission gaps.
The smarter way to use the standard
ISO 10993 is strongest when it is used as a decision framework. The earlier a team understands the biological safety questions, the easier it is to make smart design, material, testing, and documentation choices.
Need guidance on preclinical strategy, biological evaluation, or study planning? Contact TEM Biomed to discuss your development program.
